Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer

被引:6
|
作者
Kataoka, Shunichi [1 ]
Matsuno, Kei [1 ]
Sugano, Koji [1 ]
Takahashi, Kazuhisa [2 ]
机构
[1] Juntendo Tokyo Koto Geriatr Med Ctr, Div Resp Med, Koto Ku, Tokyo, Japan
[2] Juntendo Univ, Sch Med, Grad Sch Med, Bunkyo Ku, Tokyo, Japan
关键词
Endocrine system; Thyroid disease; Lung cancer (oncology); ASSOCIATION; GUIDELINES; MANAGEMENT;
D O I
10.1136/bcr-2022-250696
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid storm is a rare and life-threatening condition associated with excess thyroid hormones. Early detection of thyroid storm is the key to decreasing the morbidity and mortality associated with this condition. We present a rare case of thyroid storm induced by combination therapy with nivolumab and ipilimumab in a patient with advanced non-small cell lung cancer (NSCLC). Because of prominent hyperthyroidism with gastrointestinal symptoms and signs of heart failure, the patient was diagnosed with thyroid storm 3 weeks after initiating this combination immunotherapy. The patient had no history of thyroid disease but was positive for antithyroid antibodies. This case report suggests that thyroid function and symptoms of suspected thyroid storm should be evaluated routinely within 3 weeks from the initiation of therapy when combination therapy is administered in patients with NSCLC positive for antithyroid antibodies.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [32] Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer
    Xinyong Zhang
    Yuhua Wu
    Jialin Lv
    Xi Li
    Li Ma
    Jingying Nong
    Hui Zhang
    Na Qin
    Quan Zhang
    Guangli Shi
    Xinjie Yang
    Jinghui Wang
    Shucai Zhang
    Interdisciplinary Sciences: Computational Life Sciences, 2019, 11 : 287 - 291
  • [33] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [34] Novel immunotherapy in the treatment of advanced non-small cell lung cancer
    Santabarbara, G.
    Maione, P.
    Rossi, A.
    Palazzolo, G.
    Gridelli, C.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (12) : 1571 - 1581
  • [35] Role of immunotherapy in locally advanced non-small cell lung cancer
    Levy, A.
    Doyen, J.
    Botticella, A.
    Bourdais, R.
    Achkar, S.
    Giraud, P.
    Du, C.
    Naltet, C.
    Lavaud, P.
    Besse, B.
    Pradere, P.
    Mercier, O.
    Caramella, C.
    Planchard, D.
    Deutsch, E.
    Le Pechoux, C.
    CANCER RADIOTHERAPIE, 2020, 24 (01): : 67 - 72
  • [36] Predicting response to immunotherapy in advanced non-small cell lung cancer
    Rebordao Pires, M.
    Amorim Costa, C.
    Cunha Pereira, T.
    Monteiro, J. C.
    Domingues, I.
    Caetano, A. C.
    Meira Garcia, A. R.
    Jesus, E.
    Sousa, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S768 - S768
  • [37] Immunotherapy in treatment naive advanced non-small cell lung cancer
    Ernani, Vinicius
    Ganti, Apar Kishor
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S412 - S421
  • [38] Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study
    Katayama, Y.
    Yamada, T.
    Sawada, R.
    Harada, T.
    Chihara, Y.
    Yoshimura, A.
    Shiotsu, S.
    Okada, A.
    Yamada, T.
    Takemura, Y.
    Kohichi, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S849 - S849
  • [39] Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review
    Tandiono, J.
    Chen, S.
    Marcella, E.
    Susanto, B.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S760
  • [40] Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study
    Sepesi, B.
    Cascone, T.
    William, W.
    Lin, H.
    Leung, C.
    Weissferdt, A.
    Walsh, G.
    Rice, D.
    Roth, J.
    Mehran, R.
    Hofstetter, W.
    Antonoff, M.
    Fossella, F.
    Mott, F.
    Le, X.
    Skoulidis, F.
    Zhang, J.
    Byers, L.
    Lam, V.
    Glisson, B.
    Kurie, J.
    Blumenschein, G.
    Tsao, A.
    Lu, C.
    Altan, M.
    Elamin, Y.
    Gibbons, D.
    Papadimitrakopoulou, V.
    Lee, J.
    Heymach, J.
    Vaporciyan, A.
    Swisher, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S241 - S242